Advertising in the Panamerican Journal of Trauma, Critical Care and Emergency Surgery — A Practical India Media Guide for Pharma and Device Brands

Most pharmaceutical marketing teams we speak with have never considered placing an advertisement in a peer-reviewed surgical journal, which is precisely why the ones that do tend to dominate the conversation among the very specialists their sales teams are trying to reach. The Panamerican Journal of Trauma, Critical Care and Emergency Surgery — published out of New Delhi by Jaypee Brothers Medical Publishers — reaches a highly specific, high-prescribing audience of trauma surgeons, intensivists, and emergency physicians across South Asia and the Americas; and that specificity, frankly speaking, is worth more than a broad-reach digital campaign in most HCP marketing scenarios. What a lot of brands miss is that journal advertising India still represents one of the most underutilised channels in pharmaceutical marketing, which means the competitive noise inside PAJTCCES is considerably lower than in mainstream medical media.

What Is the Panamerican Journal of Trauma, Critical Care and Emergency Surgery?

The journal was established under the academic and editorial umbrella of the Pan-American Trauma Society, which is itself one of the most respected professional bodies in the trauma and emergency surgery space across North America, Latin America, and South Asia. PAJTCCES — as it is commonly abbreviated in media planning conversations — carries the ISSN 2278-5388 and is published as a tri-annual journal, meaning three issues are released each calendar year; this publication frequency shapes the entire advertising calendar for brands planning a sustained presence in the trauma surgery journal space. Published by Jaypee Brothers Medical Publishers (P) Ltd from their offices on Ansari Road, Daryaganj, New Delhi, the journal occupies a genuinely rare position: it is simultaneously an India medical publisher product and an internationally indexed clinical research journal.

What makes this particularly interesting from an advertiser's standpoint is the indexing footprint. PAJTCCES is indexed in databases including ResearchGate and is preserved through Portico digital preservation, which signals a level of institutional credibility that most general-interest medical publications simply cannot claim. The journal operates under a CC BY-NC 4.0 license for its open access content, which means research articles are freely accessible — and by extension, so is the brand environment in which your advertisement appears. When we have walked clients through the distinction between advertising in an open access journal versus a subscription-gated publication, the reach implications tend to shift the conversation quite significantly, because open access readership is not capped by institutional subscriptions.

At SmartAds, we always tell our clients that the credibility of the editorial environment is itself a media asset. A full-page ad appearing alongside peer-reviewed trauma and critical care research sends a very different signal to a trauma surgeon than the same creative running on a general healthcare portal; and in a category like surgical devices or critical care pharmaceuticals, that signal matters enormously to brand perception among healthcare professionals.

Who Reads PAJTCCES? Understanding the Physician Audience Across India and Beyond

The readership of the Panamerican Journal of Trauma, Critical Care and Emergency Surgery is not a homogeneous group, which is something worth understanding before you design your creative or allocate budget. The core audience is made up of trauma surgeons, critical care specialists, emergency physicians, anaesthesiologists working in trauma settings, and intensivists — a physician audience that is, almost by definition, among the highest-value targets for a specific set of pharmaceutical and device categories. In India, the concentration of this audience skews toward tertiary care hospitals, trauma centres, and teaching hospitals in metropolitan cities including Delhi, Mumbai, Chennai, Hyderabad, Bengaluru, and Kolkata; but the reach extends meaningfully into Tier 2 cities where government medical colleges maintain active trauma departments.

What a lot of people miss is the cross-border dimension of this journal's readership. Because PAJTCCES is the official publication of the Pan-American Trauma Society, its circulation includes trauma and emergency surgery specialists across Latin America and North America as well — which means a single advertisement placed in this South Asia medical journal actually delivers brand visibility medical professionals across multiple geographies. For multinational pharmaceutical companies or global surgical device manufacturers running coordinated HCP advertising campaigns, this cross-continental reach within a single media buy is genuinely unusual and worth factoring into the CPM calculation. Our experience shows that when clients map their target physician lists against the journal's readership profile, the overlap tends to be higher than they initially expect, particularly in the trauma surgery and critical care subspecialties.

The journal's readership also skews heavily toward academic and research-active physicians — the kind of healthcare professionals who attend surgical conferences, contribute to clinical guidelines, and influence formulary decisions within their institutions. Targeted advertising doctors in this cohort carries a multiplier effect that goes beyond the individual reader; a trauma surgeon who reads your device advertisement in a peer-reviewed context is far more likely to discuss it with colleagues than one who encounters the same message on a social media feed. This is, frankly, the core value proposition of medical journal advertising India, and it is one that the PAJTCCES audience exemplifies particularly well.

What Types of Advertisements Can You Place in PAJTCCES?

Print advertisement formats in PAJTCCES follow the conventions of most Jaypee Brothers Medical Publishers journals, which means the primary inventory includes full-page ads, back cover advertisement positions, inside cover ad placements (both front and back inside covers), and half-page formats. The back cover advertisement is typically the most premium position — and the most sought after — because it is the first thing a reader sees when the journal arrives, which makes it disproportionately valuable for product launches or indication expansions. Inside cover ad placements, particularly the inside front cover, carry similar premium positioning logic; and in our experience booking medical journal advertising for pharma clients, these positions tend to be claimed earliest, sometimes months ahead of the issue date.

Beyond standard print advertisement inventory, PAJTCCES through Jaypee Digital also offers digital advertisement options, which is an area that competitors' content almost entirely ignores. Banner advertisement placements on the journal's digital platform, e-print advertising, and newsletter-style sponsorship formats are available to advertisers who want to extend their reach into the online readership of the journal — a segment that has grown considerably as open access publishing has made the journal's content more widely accessible. The CPM for digital placements in a highly targeted clinical research journal works out to a figure that, when compared against programmatic HCP-targeted digital buys, often surprises our clients in a positive direction; because the audience quality here is verified and contextually relevant in a way that cookie-based physician targeting rarely achieves.

Reprints and e-prints represent a third category of advertising-adjacent investment that is frequently overlooked. A sponsored reprint of a clinical study relevant to your product — produced in partnership with Jaypee Brothers Medical Publishers and distributed at surgical conference sponsorship events or through your medical science liaison team — functions simultaneously as a credibility asset and a targeted advertising tool. The sponsored supplement format takes this a step further, which we will address in detail later in this piece; but even at the level of standard reprints, the brand visibility medical professionals associate with a well-produced clinical reprint is substantially higher than most digital content formats.

How Do You Book an Ad in PAJTCCES Through Jaypee Brothers India?

The booking process for advertising in PAJTCCES runs through Jaypee Brothers Medical Publishers (P) Ltd, whose advertising department operates from the Daryaganj, New Delhi office — specifically from their address on Ansari Road, which has been the publishing home of Jaypee Journals for several decades. The first step is to contact the advertising department directly to request the current media kit, which will contain the rate card, issue dates, ad booking deadline schedules, and technical specifications for artwork submission. We would recommend making this contact at least eight to ten weeks before your target issue date, because premium positions — particularly the back cover advertisement and inside cover ad slots — are allocated on a first-confirmed basis and tend to go quickly for the issues that coincide with major trauma surgery conferences.

Once you have confirmed your position and format, the artwork submission process requires attention to technical detail that a lot of first-time journal advertisers underestimate. Print advertisement files should generally be submitted as high-resolution PDFs at a minimum of 300 DPI, with dimensions conforming precisely to the journal's trim size and bleed specifications — and any deviation from these specifications can result in your ad being held for the following issue, which is a situation we have seen cause genuine disruption to product launch timelines. For digital advertisement formats, file specifications will typically include JPEG or PNG assets at web-optimised resolutions, along with destination URLs and any tracking parameters your team needs embedded. The ad booking deadline for each issue is typically four to six weeks before the publication date, though this varies; confirming the exact deadline with the Jaypee Brothers advertising team at the time of booking is something we always advise our clients to do in writing.

At SmartAds, we manage the entire booking and creative submission process on behalf of our clients, which removes the coordination burden from internal marketing teams and ensures that artwork reaches the publisher in the correct format on time. One pharmaceutical client we worked with — a mid-sized specialty pharma company launching a new critical care molecule — had previously missed an issue deadline because their internal agency submitted artwork at the wrong resolution; when we took over the account, we built a submission checklist specifically calibrated to Jaypee Brothers' technical requirements, and the client has not missed a deadline since across three consecutive issues of this trauma surgery journal.

What Are the Advertising Rates and Deadlines for PAJTCCES?

Frankly speaking, one of the most persistent frustrations for media planners researching PAJTCCES ad rates India is the absence of a publicly available rate card — which is a gap that exists across most Indian medical journal advertising inventory, not just this publication. What we can share from our experience booking journal advertising India across Jaypee Brothers Medical Publishers titles is that the rate structure for PAJTCCES is broadly in line with other indexed, peer-reviewed surgical journals published out of New Delhi, and the pricing reflects the journal's specialised, high-value physician audience rather than its raw circulation numbers.

A full-page ad in a journal of this profile typically falls somewhere in the ballpark of ₹25,000 to ₹60,000 per issue, depending on position — with the back cover advertisement commanding a premium of roughly 40 to 60 percent over a standard inside full-page rate, and inside cover ad positions sitting somewhere between the two. These are indicative figures based on our experience with comparable Jaypee Journals titles; the actual PAJTCCES rate card should be confirmed directly with the publisher, as rates are updated periodically and multi-issue packages — which can bring the per-issue cost down meaningfully — are negotiated individually. Digital advertisement placements through Jaypee Digital are priced separately and tend to be more flexible, with banner advertisement rates that can be structured on a per-issue or time-based model depending on the platform's current inventory structure.

What the rate card alone does not capture is the value of multi-issue commitment, which is where the real savings tend to materialise. A brand that commits to advertising across all three issues of the tri-annual journal in a single calendar year can typically negotiate a package rate that works out to a 15 to 25 percent reduction compared to booking each issue independently; and when you add a digital advertisement component to a print package, the bundled pricing from Jaypee Brothers Medical Publishers is generally more favourable than buying the two channels separately. Our experience shows that the ad booking deadline for each issue is typically firmer than advertisers expect — missing it by even a few days can mean waiting three to four months for the next issue — so building the booking calendar well in advance is not optional, it is essential.

Is Medical Journal Advertising Worth It? ROI Data for Pharma and Device Brands

The ROI question is one we get asked in almost every initial conversation about journal advertising India, and the honest answer is that it depends entirely on what you are measuring and against what benchmark. If you are comparing the CPM of a PAJTCCES print advertisement against a broad-reach digital campaign, the print number will look high; but if you are comparing it against the cost of reaching a verified, specialty-specific physician audience through any other channel — a medical conference booth, a detailing visit, a programmatic HCP-targeted digital buy — the journal starts to look considerably more efficient. The FICCI-EY Media and Entertainment Report has consistently noted that healthcare and pharmaceutical advertising in print media, particularly in specialty journals, continues to hold a disproportionate share of HCP marketing budgets relative to its share of total media spend, precisely because the audience quality justifies the investment.

We worked with a surgical device manufacturer — a company selling advanced haemostatic products used in trauma theatres — that had been running a standard mix of conference sponsorship and sales rep detailing with modest awareness metrics among trauma surgeons. When we introduced a two-issue PAJTCCES print campaign alongside a digital banner advertisement component, the brand recall scores in their post-campaign physician survey increased by a margin that surprised even their internal marketing team; the surgeons who had seen the journal ad were significantly more likely to describe the brand as "clinically credible" compared to those who had only encountered it through conference materials. This is the kind of qualitative ROI that does not show up in a CPM comparison but matters enormously when you are trying to move a surgical product through a hospital procurement committee.

To be fair, journal advertising is not a standalone channel — it works best as part of an omnichannel medical marketing strategy that combines print presence in peer-reviewed publications with digital touchpoints, conference visibility, and field force reinforcement. What we tell our clients at SmartAds is that the journal ad functions as a credibility anchor; it is the touchpoint that makes every other interaction with the brand feel more legitimate to a physician who has seen your product positioned alongside serious clinical research. The evidence-based advertising environment of a peer-reviewed journal is simply not replicable in any digital format, which is why the ROI journal advertising delivers in HCP-targeted campaigns consistently outperforms expectations when it is properly integrated into the broader media plan.

What Ethical and Regulatory Rules Apply to Medical Journal Ads in India?

This is an area where a surprising number of pharmaceutical marketing teams are underprepared, and it is worth addressing with some specificity because the consequences of non-compliance in medical journal advertising India can range from an advertisement being refused by the publisher to regulatory action under Indian law. The primary regulatory framework governing pharmaceutical advertising in India is the Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954, which prohibits advertising for certain categories of drugs and imposes strict requirements on the claims that can be made in any advertisement directed at healthcare professionals. CDSCO — the Central Drugs Standard Control Organisation — is the enforcement body, and its guidelines on drug advertising compliance are binding on all advertisers, including those placing ads in peer-reviewed journals.

On top of that, the WHO Criteria for Drug Advertisements provide an internationally recognised framework that most reputable medical publishers, including Jaypee Brothers Medical Publishers, expect advertisers to comply with as a condition of placement. These criteria require that all claims in a pharmaceutical advertisement be accurate, fair, and capable of substantiation; that the advertisement not mislead by omission; and that the approved indications, dosage, and contraindications be accurately represented. The Advertising Standards Council of India (ASCI) also maintains a code for healthcare advertising that applies to medical journal advertising, and ASCI's healthcare advertising guidelines have become increasingly referenced in publisher acceptance decisions over the past several years. Ethical advertising guidelines in this context are not optional courtesies — they are the baseline conditions under which your advertisement will be accepted for publication.

For medical device advertising, the regulatory picture is somewhat different but no less demanding. Device claims in advertisements placed in a trauma surgery journal or critical care journal must align with the device's regulatory approval status in India, and any claims relating to clinical outcomes need to be supported by published evidence. Our experience shows that the most common reason for an advertisement to be rejected or sent back for revision by a Jaypee Brothers editorial team is a claim that either exceeds the approved indication or references a study that is not yet published in an indexed journal — both of which are entirely avoidable with proper pre-submission review. We always recommend that our pharmaceutical and device clients have their medical-legal-regulatory team sign off on journal ad copy before it reaches the publisher, because revision cycles at this stage can easily cost you an issue.

How Does PAJTCCES Compare to Other Trauma and Critical Care Journals for Advertisers?

The honest comparison here requires acknowledging that the Panamerican Journal of Trauma, Critical Care and Emergency Surgery occupies a specific and somewhat unusual niche in the global surgical journal landscape — it is neither the largest nor the most broadly indexed journal in its category, but it serves a distinct audience and editorial mandate that makes it genuinely complementary to, rather than substitutable for, other publications. The Journal of Trauma and Acute Care Surgery published by LWW (Lippincott Williams and Wilkins) is the dominant global title in this space, with a significantly larger circulation and a more established international indexing profile including full PubMed and NLM indexing; but its advertising rates reflect that dominance, and for brands whose primary target is the South Asia and Latin America trauma surgery community, the cost-per-relevant-physician in PAJTCCES is likely to be more favourable. The World Journal of Emergency Surgery is another competitor in the critical care journal space, operating as a fully open access publication with a different geographic readership skew.

What sets PAJTCCES apart for India-focused advertisers is precisely its position as a South Asia medical journal with genuine Pan-American reach — a combination that is rare and that reflects the Pan-American Trauma Society's membership base. A brand that is simultaneously targeting trauma surgeons in India and in Latin American markets can, in theory, achieve meaningful reach in both geographies through a single media placement, which is a media planning efficiency that no other journal advertising India option currently replicates. To be honest, we have seen this dual-geography logic drive the decision for several multinational device clients who might otherwise have defaulted to the larger LWW title simply out of familiarity.

The indexed journal status of PAJTCCES — while not as extensive as the Journal of Trauma and Acute Care Surgery's database footprint — still carries meaningful credibility signals for the physician reader. SafetyLit, ResearchGate, and Portico digital preservation all contribute to the journal's discoverability and archival permanence, which matters to the academic surgeon who uses these databases as part of their regular research workflow. When we build a journal advertising India media plan for a client, we typically recommend PAJTCCES as a complement to a larger title rather than a straight replacement — the two together cover different segments of the trauma and critical care physician audience in ways that neither covers alone.

Can You Run Digital and Print Ads Simultaneously in PAJTCCES?

The short answer is yes, and frankly, this is where a lot of the untapped value in PAJTCCES advertising sits. Jaypee Digital — the digital publishing arm of Jaypee Brothers Medical Publishers — has been developing its online journal infrastructure, and the digital advertisement options available alongside the print edition of PAJTCCES represent a genuine omnichannel medical marketing opportunity that most advertisers have not yet fully explored. A brand that runs a full-page print advertisement in the journal simultaneously with a banner advertisement on the journal's digital platform is, in effect, reaching the same physician audience at two different points in their reading behaviour — once when the physical journal arrives at their institution, and again when they access the same content online, which is increasingly the primary mode of consumption for open access journal content.

The digital advertisement formats available through Jaypee Digital typically include leaderboard banners, sidebar placements, and interstitial formats that appear within the article reading experience — positions that carry strong contextual relevance because the reader is actively engaged with clinical content in your therapeutic area at the moment of exposure. The brand visibility medical professionals experience in this context is qualitatively different from a banner encountered on a general news site or even a healthcare portal, because the editorial context is directly relevant to the product being advertised. We have found that clients who run coordinated print and digital campaigns in the same journal issue report stronger recall in post-campaign surveys than those who run either channel in isolation, which is consistent with what the broader media effectiveness literature tells us about multi-touchpoint exposure.

One medical diagnostics company we worked with — a brand launching a point-of-care testing device relevant to emergency and trauma settings — ran a three-issue campaign in PAJTCCES that combined a back cover advertisement in print with a banner advertisement on the digital platform and a sponsored e-print of a relevant clinical study. The campaign generated a level of inbound inquiry from trauma department heads that the client's sales team described as the strongest response they had seen from any single media activity in the preceding two years; and the cost of the entire three-issue package, including creative production, was well within the budget that would have been spent on a single major conference booth. This is the kind of outcome that makes journal advertising India genuinely compelling when it is executed with the right format mix and creative strategy.

What Are Sponsored Supplements and How Can They Boost Brand Visibility?

A sponsored supplement in a medical journal is a distinct publication produced under the journal's editorial umbrella but funded entirely by a commercial sponsor — typically a pharmaceutical company or medical device manufacturer — and distributed alongside a regular issue of the journal. The key distinction between a sponsored supplement and a standard advertisement is that the supplement contains editorial content: clinical review articles, case studies, expert opinion pieces, or conference proceedings that are relevant to the sponsor's therapeutic area, written by independent clinicians and subject to editorial review, but commissioned and funded by the sponsor. This is not the same as advertorial content in a consumer publication; the editorial independence standards governing sponsored supplements in peer-reviewed journals are considerably more rigorous, and the Pan-American Trauma Society's editorial oversight of PAJTCCES means that these standards are actively enforced.

The process of commissioning a sponsored supplement through Jaypee Brothers Medical Publishers typically begins with a concept proposal submitted to the editorial team, which outlines the clinical topic, the proposed authors, and the sponsor's objectives. The editorial team will assess whether the proposed content meets the journal's scientific standards and whether the topic is genuinely relevant to the PAJTCCES readership — which is to say, trauma surgery, critical care, and emergency surgery — before approving the concept. Timelines for a sponsored supplement are considerably longer than for a standard advertisement; from initial concept approval to publication, the process typically takes somewhere between four and eight months, which means planning needs to begin well ahead of the target issue date. The cost of a sponsored supplement is also substantially higher than a standard print advertisement, reflecting the production, editorial review, and distribution investment involved; but the brand visibility medical professionals associate with a well-executed supplement is correspondingly higher.

At SmartAds, we have helped clients navigate the sponsored supplement process across several Jaypee Journals titles, and the consistent finding is that the physician response to supplement content is qualitatively different from the response to display advertising. A trauma surgeon who reads a well-constructed clinical review in a sponsored supplement — one that genuinely advances their understanding of a therapeutic area — associates that educational value with the sponsoring brand in a way that a full-page ad simply cannot replicate. The ethical advertising guidelines governing supplements require that the sponsor's involvement be clearly disclosed and that the editorial content not make direct promotional claims; working within these constraints, rather than against them, is actually what makes the format credible and effective.

PAJTCCES Publication Frequency, Circulation, and Key Details

As a tri-annual journal, PAJTCCES publishes three issues per year, which means the advertising calendar has three distinct windows — and missing any one of them means a gap of roughly four months before the next opportunity. The publication frequency is worth mapping carefully against your broader marketing calendar, particularly if you are planning a product launch or indication expansion that has a specific timing requirement; we have seen situations where a brand's launch window fell between two PAJTCCES issues, which required either accelerating the booking for the preceding issue or accepting a delayed journal presence. The ad booking deadline for each issue is typically four to six weeks before the publication date, and the Jaypee Brothers Medical Publishers advertising team can provide the exact schedule for the current year on request.

Circulation figures for PAJTCCES are not publicly disclosed in the way that consumer magazine audited circulation numbers are, which is standard practice for specialist medical journals in India and globally. What is known is that the journal's distribution covers institutional subscribers — primarily medical college libraries, hospital libraries, and trauma centre collections — as well as individual members of the Pan-American Trauma Society, which has membership across North America, Latin America, and South Asia. The open access component of the journal, accessible through Jaypee Digital and preserved through Portico digital preservation, extends the effective readership considerably beyond the print circulation; and the journal's presence on ResearchGate means that individual articles — and the advertisements appearing alongside them in the digital edition — are accessible to a global community of researchers and clinicians who may never have encountered the print version.

The journal carries the ISSN 2278-5388, which is its registered identifier in the ISSN National Centre for India system and the primary reference number used in database indexing and library cataloguing. This ISSN is the detail that confirms you are booking advertising in the correct publication when dealing with any intermediary or booking agent, and it is worth verifying against the publisher's own materials to ensure there is no confusion with similarly named titles. The National Library of India maintains records of the journal's publication history, which is another marker of its institutional standing as an India medical publisher product with a documented publishing track record.

FAQ: Advertising in the Panamerican Journal of Trauma, Critical Care and Emergency Surgery

Q: How can I advertise in the Panamerican Journal of Trauma, Critical Care and Emergency Surgery in India?

The most direct route is to contact the advertising department at Jaypee Brothers Medical Publishers (P) Ltd at their Ansari Road, Daryaganj, New Delhi office, where the Jaypee Journals advertising team handles all commercial placements for PAJTCCES. You will need to request the current media kit, which contains the rate card, issue schedule, ad booking deadline dates, and artwork specifications. Alternatively, working through a specialist media buying agency like SmartAds.in — which has established relationships with Jaypee Brothers Medical Publishers and experience managing medical journal advertising India campaigns — can simplify the process considerably, particularly if you are running a multi-format or multi-issue campaign that requires coordinated print and digital advertisement placements.

Q: What are the advertising rates for PAJTCCES magazine in India?

PAJTCCES ad rates India are not publicly listed on any website, which is consistent with the broader practice among Indian medical journal publishers of maintaining rate cards as negotiated documents rather than published price lists. Based on our experience with comparable Jaypee Journals titles, a standard full-page ad in a journal of this profile typically falls in the range of ₹25,000 to ₹60,000 per issue depending on position, with the back cover advertisement and inside cover ad positions commanding a premium over standard inside-page rates. Multi-issue packages for the full tri-annual cycle are available and typically offer meaningful discounts over single-issue bookings; digital advertisement placements are priced separately. We would always recommend requesting a formal quote from the publisher for the current year's rates, as these are updated periodically.

Q: What types of ad formats does PAJTCCES accept — print, digital, and sponsored supplements?

PAJTCCES accepts print advertisement formats including full-page ads, half-page ads, back cover advertisement, inside cover ad (front and back), and potentially quarter-page formats depending on the issue's layout. Digital advertisement options through Jaypee Digital include banner advertisement placements on the journal's online platform, e-print advertising, and newsletter-style sponsorship formats. Sponsored supplements are available as a separate commercial arrangement and involve the production of an editorially reviewed clinical content supplement funded by the sponsor; these are subject to editorial approval and require significantly longer lead times than standard display advertising. Reprints and e-prints of published articles can also be commissioned for distribution purposes.

Q: Who is the target audience of PAJTCCES — which medical specialties does it reach?

The primary physician audience of PAJTCCES consists of trauma surgeons, critical care specialists, emergency physicians, intensivists, and anaesthesiologists working in trauma and emergency settings. In India, this readership is concentrated in tertiary care hospitals, trauma centres, and academic medical institutions; the journal's Pan-American Trauma Society affiliation also delivers readership among equivalent specialists across Latin America and North America. This is a highly specific healthcare professionals audience — the kind of targeted advertising doctors environment that is particularly valuable for pharmaceutical advertising and medical device advertising in the trauma, critical care, and emergency surgery categories.

Q: How often is PAJTCCES published and when are the ad booking deadlines?

PAJTCCES is a tri-annual journal, publishing three issues per year. The ad booking deadline for each issue is typically four to six weeks before the publication date, though this should be confirmed with Jaypee Brothers Medical Publishers at the time of booking as schedules can vary. Given the publication frequency, missing a deadline means waiting approximately four months for the next available issue, which makes early booking planning particularly important for brands with time-sensitive campaign objectives.

Q: What is the ISSN number of the Panamerican Journal of Trauma, Critical Care and Emergency Surgery?

The journal's ISSN is 2278-5388, which is its registered identifier through the ISSN National Centre for India. This number should be referenced when verifying the publication's identity in database records, library catalogues, or when confirming a booking with any advertising intermediary.

Q: Who publishes PAJTCCES in India and how do I contact the advertising department?

PAJTCCES is published by Jaypee Brothers Medical Publishers (P) Ltd, headquartered at Ansari Road, Daryaganj, New Delhi. Jaypee Brothers is one of India's most established India medical publisher houses, with a portfolio of several hundred medical and surgical journals and textbooks. Their advertising department can be reached through the contact details listed on the Jaypee Journals website; we would recommend specifying that your inquiry relates to PAJTCCES advertising to ensure it is routed to the correct team.

Q: Is PAJTCCES indexed in PubMed or other major databases?

PAJTCCES has indexing presence in ResearchGate and is preserved through Portico digital preservation; its status in PubMed and NLM indexing should be verified directly with the publisher, as indexing status can evolve over time. The journal's association with the Pan-American Trauma Society and its publication through Jaypee Brothers Medical Publishers — a well-established India medical publisher — contribute to its credibility as an indexed journal, and the ISSN 2278-5388 registration confirms its formal recognition in the international serial publications system.

Q: What are the ethical and regulatory requirements for advertising in an Indian medical journal?

Pharmaceutical advertising in PAJTCCES must comply with the Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954, CDSCO drug advertising compliance guidelines, and the WHO Criteria for Drug Advertisements. The Advertising Standards Council of India (ASCI) code for healthcare advertising also applies. All claims must be accurate, substantiated, and consistent with the product's approved indications; contraindications and safety information must be appropriately represented. Medical device advertising is subject to device-specific regulatory requirements. Ethical advertising guidelines compliance is typically a condition of acceptance by Jaypee Brothers Medical Publishers, and non-compliant creatives will be returned for revision.

Q: Can non-pharmaceutical brands — medical devices, surgical equipment, hospital services — advertise in PAJTCCES?

Absolutely, and this is an area where the journal's readership profile is particularly well-matched to a range of non-pharma advertisers. Medical device advertising — particularly for products used in trauma theatres, critical care units, and emergency departments — is a natural fit for PAJTCCES. Surgical equipment manufacturers, hospital information system providers, medical education platforms, and healthcare services targeting the trauma and critical care physician audience are all viable advertisers in this journal. The ethical advertising guidelines for non-pharmaceutical categories are less prescriptive than for drugs, though ASCI codes and general standards of accuracy and non-deception still apply.

Q: What is a sponsored supplement in a medical journal and how does it differ from a standard advertisement?

A sponsored supplement is a separately produced clinical publication — containing peer-reviewed or editorially reviewed articles, case studies, or expert opinion content — that is funded by a commercial sponsor and distributed with a regular journal issue. Unlike a standard print advertisement, which is a display creative occupying a defined space in the journal, a sponsored supplement contains substantive clinical content written by independent authors and reviewed by the editorial team. The sponsor's involvement is disclosed, but the editorial content is not promotional in the direct sense; the brand visibility medical professionals associate with a supplement comes from the educational value of the content and the association with the journal's credibility, rather than from explicit product claims. Lead times for sponsored supplements are considerably longer than for display advertising — typically four to eight months from concept approval to publication.

Q: What ROI can I expect from advertising in a peer-reviewed trauma and critical care journal?

ROI from journal advertising India is best measured through physician recall studies, prescription or procurement tracking in target institutions, and brand perception surveys among the target specialty — rather than through digital metrics like click-through rates, which are not applicable to print advertisement placements. Our experience at SmartAds shows that brands running sustained multi-issue campaigns in peer-reviewed journals consistently outperform single-issue or one-off advertisers on recall and brand credibility metrics; the cumulative effect of repeated exposure in a trusted editorial environment builds a brand association that is difficult to achieve through any other HCP advertising channel. The ROI journal advertising delivers is particularly strong when the journal campaign is integrated with conference presence, field force activity, and digital touchpoints.

Q: How does PAJTCCES compare to other trauma surgery journals for advertising purposes?

PAJTCCES occupies a distinct niche as a South Asia medical journal with Pan-American reach, which differentiates it from purely international titles like the Journal of Trauma and Acute Care Surgery (LWW) and the World Journal of Emergency Surgery. For brands targeting Indian trauma surgeons and critical care specialists, PAJTCCES offers a more cost-efficient reach to the South Asia physician audience than the larger international titles; for brands with simultaneous Latin American objectives, the Pan-American Trauma Society affiliation adds a geographic dimension that no other India-published journal can match. The two channels are best understood as complementary rather than competitive in a well-constructed journal advertising India media plan.

Q: Are digital and online advertising options available in addition to print in PAJTCCES?

Yes — Jaypee Digital, the digital publishing arm of Jaypee Brothers Medical Publishers, offers digital advertisement options including banner advertisement placements on the journal's online platform, e-print advertising, and other digital formats. Running a coordinated print and digital advertisement campaign in the same journal issue is both possible and, in our experience, significantly more effective than either channel in isolation; the dual-touchpoint exposure to the same physician audience at different moments in their reading behaviour produces stronger recall and brand association than a single-channel approach.

**Q: What file formats and specifications are required for submitting advertisements to PA